On Monday, Following Stocks were among the “Top 100 Gainers” In U.S. Stock Exchange: ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Western Refining, Inc (NYSE:WNR), Gerdau SA (ADR) (NYSE:GGB), Idera Pharmaceuticals Inc (NASDAQ:IDRA)
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)’s shares picked up 4.35%, and closed at $33.35. The stock volatility for the week is 6.38%, while for the month remained 5.73%. The company holds consensus target price of $42.50.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.94 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -115.90% and Annual EPS growth for the past 5 years is considered as 4.60%.
The mean recommendation of analysts for this stock is 1.80. (where 1=Buy, 5=Sale).
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which accomplished the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has accomplished Phase II trial for the treatment of schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in partnershipwith Allergan, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Western Refining, Inc (NYSE:WNR), raised 4.34%, and closed at $49.75. The stock has price to sale ratio of 0.31, however, price to book ratio is 4.36. With recent incline, the year-to-date (YTD) performance reflected a 32.63% gain below last year. During the past month the stocks gain 5.63%, bringing three-month performance to 33.52% and six-month performance to 22.99%. The mean recommendation of analysts for this stock is 2.50. (where 1=Buy, 5=Sale).
Western Refining, Inc. operates as an independent crude oil refiner and marketer of refined products. The company operates in four segments: Refining, NTI, WNRL, and Retail. The Refining segment owns and operates two refineries that process crude oil and other feed stocks primarily into gasoline, diesel fuel, jet fuel, and asphalt; and markets refined products to various customers, counting wholesale distributors and retail chains. The NTI segment owns and operates refining and transportation assets; and operates and supports retail convenience stores primarily in the Upper Great Plains region. As of December 31, 2014, this segment operated 165 retail convenience stores and supported 89 franchised retail convenience stores.
Gerdau SA (ADR) (NYSE:GGB), enhanced 4.25%, and closed at $3.19. The company holds the market capitalization of $4.84B. For the last twelve months, the stock was able to keep return on equity at 4.80%, while return on assets at 2.50%, in response to its return on investment at 6.40%. Its 20-day moving average declined -6.83%, below 50-day moving average of -8.19%, below 200-day moving average of -30.07% from the latest market price of $3.19. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
Gerdau S.A. produces and commercializes steel products worldwide. The company provides crude steel products, which comprise billets that are used to manufacture wire rods, rebars, and merchant bars; blooms for use in the manufacture of springs, forged parts, heavy structural shapes, and seamless tubes; and slabs, which are used in the steel industry for the rolling of various flat rolled products, in addition to to produce hot and cold rolled coils, heavy slabs, and profiles.
Idera Pharmaceuticals Inc (NASDAQ:IDRA), rose 4.23%, and closed at $3.57. The stock has the beta value of 2.65, and its volatility for the week is 9.08%, while for the month it is 6.95%. The company has the market capitalization of $420.69M. The company holds the book value per share of 0.49, whereas cash per share is 0.18. Price to book ratio remained 7.29, while price to sale ratio is 5762.86. Analysts mean recommendation for the stock is said to be 2.00 (where 1=Buy, 5=sale).
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate comprises IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenstrm’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, in addition to in Phase 2 clinical trial for the treatment of dermatomyositis. Its products also comprise IMO-9200, a drug candidate in Phase 1 clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase 1/2 clinical trials for applications as immune therapies for the treatment of cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
